Cargando…
Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail
INTRODUCTION: Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360649/ https://www.ncbi.nlm.nih.gov/pubmed/35941297 http://dx.doi.org/10.1007/s00011-022-01615-w |
_version_ | 1784764367739289600 |
---|---|
author | Alkhayyat, Shadi Salem Al-kuraishy, Hayder M. Al-Gareeb, Ali I. El-Bouseary, Maisra M. AboKamer, Amal M. Batiha, Gaber El-Saber Simal-Gandara, Jesus |
author_facet | Alkhayyat, Shadi Salem Al-kuraishy, Hayder M. Al-Gareeb, Ali I. El-Bouseary, Maisra M. AboKamer, Amal M. Batiha, Gaber El-Saber Simal-Gandara, Jesus |
author_sort | Alkhayyat, Shadi Salem |
collection | PubMed |
description | INTRODUCTION: Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofibrate in the pathogenesis of SARS-CoV-2 and related complications. RESULTS: By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofibrate can reduce SARS-CoV-2 entry in human cells Fenofibrate also suppresses inflammatory signaling pathways, which decreases SARS-CoV-2 infection-related inflammatory alterations. In conclusion, fenofibrate anti-inflammatory, antioxidant, and antithrombotic capabilities may help to minimize the inflammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction between SARS-CoV-2 and ACE2, fenofibrate can directly reduce the risk of SARS-CoV-2 infection. CONCLUSIONS: As a result, fenofibrate could be a potential treatment approach for COVID-19 control. |
format | Online Article Text |
id | pubmed-9360649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-93606492022-08-09 Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail Alkhayyat, Shadi Salem Al-kuraishy, Hayder M. Al-Gareeb, Ali I. El-Bouseary, Maisra M. AboKamer, Amal M. Batiha, Gaber El-Saber Simal-Gandara, Jesus Inflamm Res Review INTRODUCTION: Fenofibrate is an agonist of peroxisome proliferator activated receptor alpha (PPAR-α), that possesses anti-inflammatory, antioxidant, and anti-thrombotic properties. Fenofibrate is effective against a variety of viral infections and different inflammatory disorders. Therefore, the aim of critical review was to overview the potential role of fenofibrate in the pathogenesis of SARS-CoV-2 and related complications. RESULTS: By destabilizing SARS-CoV-2 spike protein and preventing it from binding angiotensin-converting enzyme 2 (ACE2), a receptor for SARS-CoV-2 entry, fenofibrate can reduce SARS-CoV-2 entry in human cells Fenofibrate also suppresses inflammatory signaling pathways, which decreases SARS-CoV-2 infection-related inflammatory alterations. In conclusion, fenofibrate anti-inflammatory, antioxidant, and antithrombotic capabilities may help to minimize the inflammatory and thrombotic consequences associated with SARSCoV-2 infection. Through attenuating the interaction between SARS-CoV-2 and ACE2, fenofibrate can directly reduce the risk of SARS-CoV-2 infection. CONCLUSIONS: As a result, fenofibrate could be a potential treatment approach for COVID-19 control. Springer International Publishing 2022-08-08 2022 /pmc/articles/PMC9360649/ /pubmed/35941297 http://dx.doi.org/10.1007/s00011-022-01615-w Text en © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Alkhayyat, Shadi Salem Al-kuraishy, Hayder M. Al-Gareeb, Ali I. El-Bouseary, Maisra M. AboKamer, Amal M. Batiha, Gaber El-Saber Simal-Gandara, Jesus Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title | Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title_full | Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title_fullStr | Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title_full_unstemmed | Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title_short | Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail |
title_sort | fenofibrate for covid-19 and related complications as an approach to improve treatment outcomes: the missed key for holy grail |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360649/ https://www.ncbi.nlm.nih.gov/pubmed/35941297 http://dx.doi.org/10.1007/s00011-022-01615-w |
work_keys_str_mv | AT alkhayyatshadisalem fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT alkuraishyhayderm fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT algareebalii fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT elbousearymaisram fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT abokameramalm fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT batihagaberelsaber fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail AT simalgandarajesus fenofibrateforcovid19andrelatedcomplicationsasanapproachtoimprovetreatmentoutcomesthemissedkeyforholygrail |